Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Featured Webinar

Featured Article

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813-823. doi:10.1056/NEJMoa2211437

Reviewers

Methodological Reviewer

Carolyn Nessim, MD, MSc, FRCSC, FACS, University of Ottawa

Clinical Reviewer

Andrea Covelli, MD, PhD, FRCSC, University of Toronto

Clinical Reviewer

Mai-Kim Grevais, MD, FRCSC, Université de Montréal

Questions

Please read the above article and consider the following questions:

1. What is the clinical question being addressed?
2. What is the study design? Is it appropriate?
3. What are the sources of data?
4. Are the data accurate and valid?
5. What was the intervention and how was it assessed?
6. What outcomes were considered?
7. Are there other clinically important outcomes that should be considered?
8. How large and precise was the difference in the outcome?
9. Are there any factors (confounders) that might explain the differences in the results?
10. State the conclusion. Have the authors addressed the clinical question posed?
11. Does the evidence support the conclusion?